HMG-CoA Reductase InhibitorsGerd Schmitz, Michael Torzewski Birkhäuser, 6. dec. 2012 - 151 strani HMG-CoA reductase inhibitors (statins) are established drugs for the treatment of hypercholesterolemia. Furthermore, they induce regression of vascular atherosclerosis as well as reduction of cardiovascular-related morbidity and death in patients with and without coronary artery disease. This book deals with statins which have substantially altered the approach to therapy of atherosclerosis and its sequelae. Emphasis is placed on the scientific background to the discoveries and the development of the therapy, including an overview of the current state of knowledge of the drugs. Clinical data are reviewed extensively. This book not only provides the reader with valuable information but also stimulates further research into the pathogenesis of atherosclerosis and the mechanisms behind the action of effective statins. It sets the stage for creative thinking among scientists of many disciplines for the accomplishment of our ultimate goals in treating atherosclerosis and its sequelae. This topical volume... |
Vsebina
Margaret E Brousseau and Ernst J Schaefer | 19 |
Jörg Kotzka Wilhelm Krone and Dirk MüllerWieland | 35 |
Gerd Schmitz and Michael Torzewski | 55 |
Koichi Node and James K Liao | 81 |
HansP Thomas and Elisabeth SteinhagenThiessen | 99 |
Helena K Gylling and Tatu A Miettinen | 121 |
Colin Berry Andrew Davie and John McMurray | 135 |
| 149 | |
Druge izdaje - Prikaži vse
Pogosti izrazi in povedi
3-hydroxy-3-methylglutaryl coenzyme Acad Sci USA activity AFCAPS/TexCAPS apoB apoB secretion Arterioscler Thromb Vasc atherosclerosis atherosclerotic lesions atherosclerotic plaques atorvastatin Biol Chem C-reactive protein Cardiol cardiovascular events cellular cerivastatin cholesterol lowering cholesterol synthesis Circulation clinical coenzyme coenzyme A reductase coronary artery coronary events coronary heart disease cost-effectiveness decreased diabetes drug effects of statins Engl enzyme expression gene Goldstein JL HMG-CoA reductase inhibitors HMGR human hypercholesterolemia increase inhibition LDL cholesterol LDL receptor lipid lipid-lowering liver lovastatin low density lipoprotein macrophages metabolism mevalonate mevalonate pathway mevastatin mg/dl mice Miettinen mmol/l monocytes myocardial infarction Natl Acad Sci patients platelet pravastatin Prevention Study primary prevention Proc Natl Acad reduced regulation risk factors role rosuvastatin Scandinavian Simvastatin Survival secondary prevention serum cholesterol simvastatin Simvastatin Survival Study SREBP-1c SREBP-2 SREBPs statin therapy statins sterol regulatory element sterol regulatory element-binding stroke synthase Thromb Vasc Biol tion trial vascular VLDL WOSCOPS